Press releases

First-of-its-kind, all-in-one HD-mapping and dual energy (pulsed field and radiofrequency) ablation catheter Highly anticipated by electrophysiologists for its innovation and demonstrated safety...

APHRS: New data confirm robust long-term durability and highly efficient procedure performed without fluoroscopy Successful launch in Japan follows recent reimbursement approval Approvals across...

HRS late breaking data: SPHERE Per-AF trial demonstrates novel all-in-one system delivers exceptional results, plus increased efficiency and improved quality of life DUBLIN and BOSTON, May 17,...

Global LEADR clinical trial meets safety and effectiveness objectives; results presented at Heart Rhythm 2024 and simultaneously published in Heart Rhythm DUBLIN and BOSTON, May 17, 2024...

EHRA late-breaking data: Results highlight efficacy, safety, and durability of the novel PFA catheter that is fully integrated with Affera™ Mapping and Ablation System DUBLIN and BERLIN, April...

New data from largest head-to-head randomized control TAVR trial demonstrates non-inferior clinical outcomes and superior valve performance for Evolut TAVR compared to Sapien™ at one year DUBLIN and

Despite prevalence of chronic conditions associated with aortic stenosis in women over 65, the majority have never been referred to a cardiologist; Racial disparities may present further...

The Evolut™ FX+ TAVR system leverages market-leading valve performance with addition of larger windows to facilitate coronary access DUBLIN, March 27, 2024 /PRNewswire/ -- Medtronic plc (NYSE:...

New pacemakers offer 40% more battery life,1 extend Medtronic legacy of pacing leadership DUBLIN, Jan. 5, 2024 /PRNewswire/ -- Medtronic plc (NYSE: MDT), a global leader in healthcare technology,...

Safe, efficient, and effective treatment for both paroxysmal and persistent atrial fibrillation DUBLIN, Dec. 13, 2023 /PRNewswire/ -- Medtronic plc (NYSE: MDT), a global leader in healthcare...

The Symplicity™ blood pressure procedure offers patients a new adjunct approach to lowering blood pressure Approval is the culmination of ten years of clinical research and development of the...

TCT 2023: Medtronic adds to the body of evidence for Evolut TAVR with late-breaking clinical trial data from the Evolut Low Risk Trial DUBLIN and SAN FRANCISCO, Oct. 24, 2023 /PRNewswire/ --...

First-of-its-kind Aurora EV-ICD™ system offers single device, single procedure with lead placed outside of heart and veins DUBLIN, Oct. 23, 2023 /PRNewswire/ -- Medtronic plc (NYSE:MDT), a...

Late-breaking data at Heart Rhythm 2023 underscore performance of first-of-its-kind investigational defibrillator with the lead placed under the breastbone, outside the heart and veins...

AccuRhythm AI algorithms now cleared by FDA for the Reveal LINQ ICM; enhancements made to the AF algorithm for the LINQ II ICM DUBLIN, May 16, 2023 /PRNewswire/ -- Medtronic plc (NYSE: MDT) today...

New pacemakers offer 40% more battery life,1 extend Medtronic legacy of pacing leadership DUBLIN, May 1, 2023 /PRNewswire/ -- Medtronic plc (NYSE: MDT), a global leader in healthcare technology,...

First of its kind, all-in-one Sphere-9™ Catheter with pulsed field ablation, radiofrequency, and high density mapping integrated with intuitive mapping and navigation platform DUBLIN, March 15, 2023

ACC.23/WCC late-breaking data: PULSED AF, one of the most rigorously executed PFA clinical studies to date, exceeds safety and efficacy performance goals in the treatment of paroxysmal and...

EV-ICD defibrillation lead placed outside of heart and veins, preserving vasculature DUBLIN, Feb. 17, 2023 /PRNewswire/ -- Medtronic plc (NYSE:MDT) has received CE (Conformité Européenne) Mark...

ISC23: Late-breaking results from STROKE AF study reinforce importance of long-term continuous cardiac monitoring in ischemic stroke patients DUBLIN and DALLAS, Feb. 8, 2023 /PRNewswire/ --...

SPHERE Per-AF will determine the safety and effectiveness of the Sphere-9 cardiac ablation and mapping catheter with the Affera mapping and navigation system DUBLIN, Dec. 5, 2022 /PRNewswire/ --...

Medtronic plc (NYSE:MDT), a global leader in healthcare technology, today announced the six-month results from the full cohort of the SPYRAL HTN-ON MED clinical trial. The data were presented...

Medtronic "Conduction System Pacing" Expanded Indication Now Includes Left Bundle Branch Area Pacing in Addition to His-Bundle Pacing for Patients with Slow Heart Rates DUBLIN, Oct. 17, 2022...

The LINQ II ICM is the first continuous, long-term cardiac monitor cleared by FDA for the pediatric patient population DUBLIN, Sept. 20, 2022 /PRNewswire/ -- Medtronic plc (NYSE:MDT), a global...

Long-term analysis from landmark renal denervation trial presented as Late Breaking Clinical Science, published simultaneously in The Lancet Data add to growing body of evidence supporting the...

Acquisition adds mapping and navigation platform to company's cardiac ablation portfolio and brings an integrated system of diagnostic and therapeutic tools to address a broad spectrum of arrhythmias

Late-breaking data presented at ESC Congress 2022 and simultaneously published in The New England Journal of Medicine confirms implant procedure safety and defibrillation success DUBLIN and BARCELONA,

Partnership underscores Medtronic's commitment to investing in innovative technologies that support physicians and patients from diagnosis to treatment CathWorks' FFRangio® System provides...

Medtronic adds to SPYRAL HTN Global Clinical Program with late breaking clinical data for SPYRAL HTN-ON MED and GSR-DEFINE DUBLIN and PARIS, May 17, 2022 /PRNewswire/ -- Medtronic plc (NYSE: MDT),...

The Onyx Frontier™ drug-eluting stent offers an innovative delivery system and builds upon the acute performance and clinical data from the Resolute Onyx™ drug-eluting stent DUBLIN, May 13, 2022 /

Medtronic adds to its robust clinical program with long-term data demonstrating the continued blood pressure lowering effect of the Symplicity renal denervation procedure Medtronic also completes...

Medtronic plc (NYSE:MDT), a global leader in healthcare technology, today announced that the Freezor™ and Freezor™ Xtra Cardiac Cryoablation Catheters are approved by the U.S. Food and Drug...

Medtronic plc (NYSE:MDT), a global leader in healthcare technology, today announced it has received approval from Japan's Ministry of Health, Labor and Welfare for the sale and reimbursement of...

First Medtronic TAVR system approved in China for patients with symptomatic severe aortic stenosis DUBLIN, Jan. 10, 2022 /PRNewswire/ -- Medtronic plc (NYSE:MDT), a global leader in healthcare...

Acquisition to expand company's cardiac ablation portfolio, including first-time entry into mapping and navigation, within one of the fastest growing medtech markets DUBLIN, Jan. 10, 2022...

Transfemoral access added into landmark APOLLO Pivotal Trial following IDE approval from FDA DUBLIN and ORLANDO, Fla., Nov. 6, 2021 /PRNewswire/ -- Medtronic plc (NYSE:MDT), a global leader in...

TCT 2021: Intermediate risk TAVR patients demonstrate strong hemodynamics and stable valve performance at five years DUBLIN and ORLANDO, Fla., Nov. 5, 2021 /PRNewswire/ -- Medtronic plc...

New data from Medtronic Patient Preference study presented at TCT 2021; Medtronic adds to its clinical leadership for renal denervation with launch of the SPYRAL AFFIRM study DUBLIN and ORLANDO,...

Medtronic plc (NYSE: MDT), the global leader in medical technology, today announced the publication of a study demonstrating, through the use of a Medtronic continuous rhythm monitoring device,...

Medtronic plc (NYSE: MDT), the global leader in medical technology, today announced a pilot program with Mpirik to address disparities in care associated with the prevention of sudden cardiac...

Results Presented at ESC 2021 Show Micra TPS Compares Favorably to Traditional Pacemakers DUBLIN, Aug. 27, 2021 /PRNewswire/ -- Medtronic plc (NYSE:MDT), the global leader in medical technology,...

Medtronic plc (NYSE: MDT), the global leader in medical technology, today announced U.S. Food and Drug Administration (FDA) approval of its newest-generation, self-expanding transcatheter aortic...

AI Algorithms Enhance LINQ II™ Insertable Cardiac Monitor Diagnostic Accuracy for Improved Management of Patients DUBLIN, July 28, 2021 /PRNewswire/ -- Medtronic plc (NYSE:MDT), the global...

Medtronic plc (NYSE: MDT), the global leader in medical technology, today announced new data from the landmark WRAP-IT study published in Heart Rhythm, demonstrating a significantly lower...

Medtronic Prevail DCB™ Designed to Treat Complex Lesions with Superior Deliverability, Rapid Absorption of Paclitaxel DUBLIN, July 26, 2021 /PRNewswire/ -- Medtronic plc (NYSE: MDT), the global...

DEFINE AFib Study Will Leverage Data from Medtronic Insertable Cardiac Monitors and Medtronic Discovery App™ with the Goal of Informing Atrial Fibrillation (AF) Management Strategies DUBLIN,...

- First and Only Approval to Indicate Cryoablation as an Initial Rhythm Control Strategy - Offers Safe, Effective Alternative to Antiarrhythmic Drug Therapy for the Prevention of Atrial Arrythmia...

Medtronic plc (NYSE:MDT), the global leader in medical technology, today announced clinical trial results from the STROKE AF trial demonstrating the superiority of the Reveal LINQ™ Insertable...

- Company Developing Support Program for Current HVAD Patients - Medtronic Coordinating with Global Regulators to Assure Patient Access to Left Ventricular Assist Devices DUBLIN, June 3, 2021...

Medtronic plc (NYSE:MDT), the global leader in medical technology, today announced the complete two-year outcomes from the landmark Evolut Low Risk Trial comparing the minimally invasive Evolut™...